Orion Oyj/€ORNBV
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Orion Oyj
Orion Oyj is a Finnish pharmaceutical and diagnostics company engaged primarily in the research, development, manufacturing, and marketing of pharmaceuticals and active pharmaceutical ingredients. It operates through two main segments: the Pharmaceuticals segment, which includes proprietary drugs, specialty products, and animal health, and the Diagnostics segment, which comprises the Orion Diagnostica company focused on diagnostic tests. Founded in 1917, Orion is headquartered in Espoo, Finland, and operates globally with a significant presence in the Nordic countries and significant partnerships worldwide. Orion's strategic focus includes a strong emphasis on its proprietary drug portfolio, particularly in the central nervous system and oncology sectors, which constitutes a crucial component of its competitive strengths.
- Ticker
- €ORNBV
- Sector
- Health
- Primary listing
- XHEL
- Employees
- 4,215
- Headquarters
- Espo, Finland
- Website
- www.orionpharma.com
Orion Oyj Metrics
BasicAdvanced
€14B
21.00
€4.68
0.28
€1.80
1.83%
Price and volume
Market cap
€14B
Beta
0.28
52-week high
€99.00
52-week low
€57.30
Average daily volume
176K
Dividend rate
€1.80
Financial strength
Current ratio
2.722
Quick ratio
1.613
Long term debt to equity
0.069
Total debt to equity
0.09
Dividend payout ratio (TTM)
36.85%
Interest coverage (TTM)
115.22%
Profitability
EBITDA (TTM)
884.4
Gross margin (TTM)
67.44%
Net profit margin (TTM)
30.26%
Operating margin (TTM)
38.11%
Effective tax rate (TTM)
20.30%
Revenue per employee (TTM)
€520,000
Management effectiveness
Return on assets (TTM)
27.42%
Return on equity (TTM)
54.49%
Valuation
Price to earnings (TTM)
21.003
Price to revenue (TTM)
6.355
Price to book
9.87
Price to tangible book (TTM)
11.49
Price to free cash flow (TTM)
35.336
Free cash flow yield (TTM)
2.83%
Free cash flow per share (TTM)
2.781
Dividend yield (TTM)
1.83%
Growth
Revenue change (TTM)
33.66%
Earnings per share change (TTM)
110.07%
3-year revenue growth (CAGR)
23.24%
10-year revenue growth (CAGR)
7.51%
3-year earnings per share growth (CAGR)
55.92%
10-year earnings per share growth (CAGR)
10.58%
3-year dividend per share growth (CAGR)
4.00%
10-year dividend per share growth (CAGR)
3.31%
What the Analysts think about Orion Oyj
Analyst ratings (Buy, Hold, Sell) for Orion Oyj stock.
Analyst projections of the future price of Orion Oyj stock.
Bulls say / Bears say
Orion lifted its 2026 sales outlook to €2.07–2.14 billion and operating-profit outlook to €730–790 million after royalty income grew faster than expected. The upgrade supports near-term earnings momentum. (Orion)
Phase 3 DASL-HiCaP results showed darolutamide cut the risk of metastasis or death by 58% in high-risk prostate cancer. The treatment is not approved for this setting, but success could open a further market for Orion-discovered darolutamide. (Financial Times)
Orion secured exclusive European commercialisation rights for Qilu’s pembrolizumab biosimilar, adding a partnered oncology opportunity to its portfolio. Qilu is developing and supplying the drug, limiting Orion’s need to fund its development itself. (Orion)
Orion’s profit outlook relies heavily on Nubeqa royalties, which can fluctuate with delivery timing and currency moves. The company says the exact royalty level is difficult to predict, so a shortfall could have a material effect on profit. (Orion)
Orion’s partner Tenax reported that the Phase 3 LEVEL trial of oral levosimendan missed both its primary and key secondary endpoints. That setback weakens the near-term case for the licensed treatment and leaves its next development steps uncertain. (Orion)
Nubeqa’s longer-term value depends in part on patent protection extending beyond the 2033 expiry implied by current exclusivity. The outcome remains uncertain: litigation is ongoing, with a key US trial expected in 2027. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.
Orion Oyj Financial Performance
Revenues and expenses
Orion Oyj Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Orion Oyj
AllEURUSDGBP
Fund name | Fund size | €ORNBV weighting |
|---|---|---|
SPDR S&P Euro Dividend Aristocrats€EUDV | €1.8B | 2.06% |
SPDR S&P Euro Dividend Aristocrats£EUDV | €1.8B | 2.06% |
iShares EURO STOXX Mid€DJMC | €595M | 1.30% |
iShares EURO STOXX Mid Cap£DJMC | €595M | 1.30% |
iShares Healthcare Innovation£DRDR | $1.3B | 1.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.